Gilead technology said on September 13 that it would pay 21 billion US dollars (1 US dollar about 6.78 yuan) to acquire biotechnology enterprise American immunomedicine company and its precious breast cancer drugs, US media said.
According to the Wall Street Journal website on September 13, the agreement marks the value of immunomedicine, a cancer drug company.
Shares of immunomedicine companies have soared recently, with a market value of about $10 billion. That means Gilead will take ownership of the company at a premium.
Gilead agreed to buy immunomedicine for $88 A share in cash, while the company's shares closed at $42.25 on November 11, a premium of 108%, the report said.
Gilead chief executive Daniel Odey said the agreement will help Gilead speed up its expansion into cancer treatment.
"This allows us to quickly advance what we have done over the past few years, which is to develop a real franchise and product line in the field of cancer treatment," Odey said in an interview. And it's not really complete until you have a product that's approved for sale. "
Trotelvy, a breast cancer drug sold by immunomedicine, is attractive to many large pharmaceutical companies, the report said. Many of these companies are looking to add more fast-growing cancer therapies to their product lines.
Breast cancer treatment is one of the most profitable segments of the global cancer drug market. The size of the sector will reach $157 billion this year, according to evaluation report evaluate pharma.
Breast cancer drug market has become one of the most popular fields in pharmaceutical industry. Increased awareness of breast cancer opens up new opportunities for pharmaceutical companies to find treatments that help patients, and these treatments can be expensive.
As a result, the largest pharmaceutical companies, such as AstraZeneca, Pfizer and GlaxoSmithKline, have taken actions to seize the beachhead in cancer treatment and compete with Novartis and Roche holdings in Switzerland.
The premium has skyrocketed as all parties want access to cancer treatments, especially drugs that have been approved by regulators like Trovix.